Kornimate/medical-research-clean huggingface dataset:
high flow nasal cannula in children with status asthmaticus

Conditions: Status Asthmaticus

Summary: in france, over 2.5 million people suffer from asthma, including one-third of children. this is the chronic respiratory disease leading to the highest rate of hospitalization. the conventional oxygen delivery means in children are the non-rebreather face mask or low flow nasal cannula (standard oxygen therapy - sot). new non-invasive ventilatory support systems such as high flow nasal cannula (hfnc) are emerging. these are nasal cannulas allowing the delivery of a high air (or oxygen) flow, exceeding the inspiratory flow of patients with acute respiratory failure, allowing to deliver a slight positive expiratory pressure while ensuring humidification and warming of the airways. aerosol administration is also possible with excellent efficiency and without interrupting respiratory assistance. physiological data and clinical studies in other pathologies suggest the interest of this technique during the asthma attack, but no comparative study currently exists in this indication. the hfncs could have their place upstream of non invasive ventilation (niv), thus replacing non-rebreather face mask sometimes not tolerated by the children. the investigators's hypothesis is that hfncs could improve patients' health faster, reduce the use of other ventilatory assistance (niv, invasive ventilation) and reduce the duration of hospitalization in intensive care units or continuous monitoring units (cmu).


Eligibility criteria:
inclusion criteria: * age ≥ 6 months and \<18 years old * hospitalized in picu with status asthmaticus defined by 1. a pram score \> 7 with no response at h2 to the conventional treatment according to the gina (global initiative for asthma guidelines) protocol: oxygen therapy, continuous nebulization of beta2 agonist for at least one hour then every hour, oral or intravenous corticosteroid (ie methylprednisolone 2mg/kg/j) 2. or with hypercapnic acidosis (pco2 \> 45 mmhg and ph \< 7,35) * informed consent signed by at least on parent or legal guardians prior to inclusion and oral consent of the other parent if absent exclusion criteria: * non-corrected congenital heart disease, or neuromuscular disease, or chronic respiratory disease (pulmonary or bronchial fibrosis, cystic fibrosis), or ena disease (laryngo or tracheo malacia), scoliosis or chronic metabolic disease * need for non-invasive or invasive ventilation (glasgow comas scale \<8, hemodynamic instability, refractory hypoxemia, cardiac arrest) * pneumothorax confirmed on the x-ray * no national health coverage

Keywords: children status asthmaticus hfnc
assertive community treatment in copenhagen

Conditions: Schizophrenia; Bipolar Disorder

Summary: the aim of the study is to evaluate the effect of assertive community treatment in copenhagen in two regions compared with two regions where this treatment was not implemented. the effect on user satisfaction, use of bed days, social network, global assessment of functioning, substance misuse will be evaluated.

in area where assertive community treatment was implemented 100 patients had filled in a form regarding their social situation. they were interviewed after one year and asked about user satisfaction and followed up in danish registers. register information was extracted concerning vital status, cause of death, use of psychiatric services and criminal record. the same procedure was carried out for a comparison group, carefully matched, from other regions in copenhagen, where assertive community treatment was not implemented.

Eligibility criteria:
inclusion criteria: * user of bed days exceeded 40 days last two years; or * 4+ admissions during last two years; or * a second diagnosis of substance misuse; or * non compliance with medication or outpatient visits in usual settings; or * being unable to use other existing services exclusion criteria: * forensic patient with a sentence to stay in hospital

Keywords: schizophrenia assertive community treatment
performance of safety of silkam® suture material in oral surgery

Conditions: Tooth, Impacted; Teeth Impact; Tooth Impaction; Mucosal Wound

Summary: assessment of silkam® suture material in mucosal closure in oral surgery (mucosal sutures). a prospective, monocentric, single arm observational study.

the aim of this non interventional study is to collect systematically and proactively different clinical parameters regarding safety, effectiveness, and performance of silkam® suture material under the daily routine clinical practice when is intended to be used for oral surgery. all patients enrolled will be prospectively followed until suture removal, which takes place approximately one week post-operatively.

Eligibility criteria:
inclusion criteria: * patients undergoing mucosal wound closure using silkam® as suture material in oral surgery (in the event that more than one incision is performed in the same patient, only one incision will be considered). exclusion criteria: * patients taking medication that might affect wound healing * patients having a condition that might affect wound healing. * patients with hypersensitivity or allergy to the suture material. * participation in another (randomized) clinical trial / clinical study. * non-compliance of patient (i.e. dementia).

Keywords: tooth distraction removal of impacted teeth oral surgery dental implant observational study
efficacy of dialectical behavior therapy versus cams-informed supportive psychotherapy on self harming behavior

Conditions: Borderline Personality Disorder; Suicide

Summary: purpose: the purpose of this study is to investigate the efficacy of dialectical behavior therapy (dbt) versus cams (collaborative assessment and management of suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder. hypothesis: the hypothesis is 16 weeks of treatment with dialectical behavior therapy (dbt) after a defined manual has a higher efficacy than cams-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (bdp). method: the investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of dbt-treatment as a higher efficacy than cams-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. the trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. there will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Eligibility criteria:
inclusion criteria: * 18-65 years of age. * newly suicide attempt within one month of the inclusion date. * a minimum of two characteristics in the dsm-iv borderline personality disorder (bpd) * informed consent. exclusion criteria: * severe depression. * bipolar disorder. * psychosis within the schizophrenic spectrum. * anorexia nervosa. * substance abuse. * mental retardation. * dementia. * lack of informed consent

Keywords: borderline personality disorder traits suicide prevention self-harm dialectical behavior therapy dbt collaborative assessment and management of suicidology cams
intermediate ind severe illness covid-19 cp

Conditions: Severe Acute Respiratory Syndrome; COVID

Summary: beyond supportive care, there are currently no proven therapeutic options for pneumonia due to coronavirus disease (covid-19), the infection caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2). human convalescent plasma is an option for treatment of covid-19 and will be available when sufficient numbers of people have recovered. such persons should have high titer neutralizing immunoglobulin-containing plasma.

subjects will receive open-label screened plasma from covid-19+ clinically resolved individuals (≥14 days post-resolution). dosing of single or double plasma units (weight based \ 90kg) will be administered on days 0, 2, 4, 6, and 8 (based on plasma availability), or until futility (if either occurs before day 8) is determined by the icu. doses can be omitted at the discretion of the treating clinician (e.g., trali events are 100% donor-dependent and do not prohibit future transfusions). the study drug is the investigational product, anti-sars-cov-2 convalescent plasma obtained from the american red cross or local plasma supply (medicdal center or city/region-wide shared blood bank) from patients identified as having recovered from covid-19. donors and samples will be screened for infections transmitted via transfusion (e.g. hiv, hbv, hcv, wnv, htlv-i/ii, t.cruzi, zikv) both through the use of the uniform donor questionnaire and fda mandated blood donor screening tests. plasma will be collected using apheresis technology or whole blood collection in accordance with standard fda and blood bank protocols.

Eligibility criteria:
inclusion criteria: * laboratory confirmed covid-19 * severe or immediately life threatening covid-19 * dyspnea * respiratory frequency \> 30/minute * blood oxygen saturation \<93% * life-threatening disease is defined as the following * respiratory failure. * septic shock, and/or, * multiple organ dysfunction or failure. exclusion criteria: * contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products). * other documented uncontrolled infection. * severe dic needing factor replacement, ffp, cryoprecipitate. * on dialysis. * active intracranial bleeding. * clinically significant myocardial ischemia.

Keywords: corona virus convalescent plasma
changes of functional status, symptoms distress and quality of life in patients undergoing coronary artery bypass graft (cabg) surgery

Conditions: Coronary Artery Bypass Graft Surgery

Summary: the purpose of this study is to explore the changes of functional status, symptoms distress and quality of life in patients undergoing coronary artery bypass graft (cabg) surgery.

this is an observational cohort study. the participants will be inpatients undergoing elective cabg surgery at one tertiary medical center. functional status (including activity of daily living, cognitive and nutritional status), symptom distress, and quality of life will be measured at multiple points: pre-surgery, day 1 to 7 post-surgery, before discharge, and 2-4 weeks after discharge. structured questionnaire will be used to collect demographic and medical characteristics. the barthel index, hand-held dynamometer, 6-minute walking test, mini-nutritional assessment (mna), mini-mental state examination (mmse), confusion assessment method (cam), symptoms distress scale, and short-form-36 health survey (sf-36) will be used to collect functional data and compared for changes. the trajectory of functional status, symptoms distress, and quality of life will be further analyzed. the findings will add to the literature by raising the awareness on changes of functional status, symptoms distress, and quality of life for patients undergoing elective cabg so targeted and timely intervention could be developed and planned.

Eligibility criteria:
inclusion criteria: * receive elective coronary artery bypass surgery * able to communicate in chinese and taiwanese * walk independently or use walker * length of stay is over 7 days exclusion criteria: * unable to walk * mechanical ventilation * neural or muscle disease to influence ambulation(ex: parkinson disease) * asthma * severe psychotic disorder that prevents patient from participating in test

Keywords: cabg functional status symptoms distress quality of life the trajectory of functional status the changes of symptoms distress the changes of quality of life
clinical value of remote ischemic preconditioning

Conditions: Heart Diseases; Atrial Fibrillation

Summary: objectives: despite utilization of available means for cardioprotection during cardiac surgery, myocardial injury still occurs. further improvement of cardioprotection is therefore necessary. remote ischemic preconditioning (ripc) is an easy and non-invasive method. laboratory research has shown promising results regarding myocardial survival during open heart surgery, but the clinical value of ripc is still largely unknown. the investigators hypothesize that ripc before coronary artery bypass grafting (cabg) reduces the incidence of postoperative atrial fibrillation (poaf).


Eligibility criteria:
inclusion criteria: * elective isolated on-pump cabg surgery * informed consent exclusion criteria: * patients with a severe pulmonary disease * patients with renal failure (gfr\<30 ml/min/1.73 m2) * patients with liver failure * peripheral vascular disease affecting the upper limbs * patients on sulfonylurea derivatives. * patients with atrial fibrillation in their case history * prior cardiac surgery (re-operations)

Keywords: ischemic preconditioning coronary artery bypass preoperative care postoperative period
safe renal function in long term heart transplanted patients

Conditions: Kidney Diseases; Heart Transplantation

Summary: the purpose of this study is to verify whether the reduction of cyclosporine dosages associated with everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy


Eligibility criteria:
inclusion criteria: * heart transplant patients with more than 1 year of follow-up * creatinine lower than 3.5 mg/dl * gfr higher than 20 ml/min (calculated with cockcroft-gault formula) * cyclosporine in maintenance immunosuppressive therapy * patient must be able to sign an approve informed consent * prior history of acute rejection within the last 3 months * females of childbearing age may be included if pregnancy is excluded and acceptable contraception measures are used exclusion criteria: * patients who are recipients of multiple organ transplants * prior or current use of sirolimus or everolimus * history of acute rejection within the last 6 months * coronary artery bypass surgery or other cardiac surgery in the past 3 months * patient not able to attend all follow-up evaluations

Keywords: kidney diseases heart transplantation everolimus cyclosporine toxicity
endoscopy for assessment of mucosal healing in ibd

Conditions: Crohn´s Disease; Ulcerative Colitis

Summary: inflammatory bowel disease (ibd) encompasses two major forms of chronic intestinal disorders, crohn's disease and ulcerative colitis (uc). diagnosis is based on several macroscopic and histologic features including patterns of inflammation, crypt abscesses and granulomas. i-scan use an endoscopic image from the video processor and reconstruct virtual images in real time, resulting in an improved contrast of the capillary patterns and enhancement of the mucosal surface (so called virtual chromoendoscopy). the main objective of this study is to determine endoscopic features of mucosal healing in patients with ibd and to compare these features to clinical and histological data in order to establish a new endoscopic classification of mucosal healing and to evaluate mucosal healing as a parameter of remission and relapse.


Eligibility criteria:
inclusion criteria: * written informed consent * age 18-85 years * ability of subjects to understand character and individual consequences of clinical trial * subjects undergoing colonoscopy exclusion criteria: * inability to provide written informed consent * severe coagulopathy (prothrombin time \ 50 s) * pregnancy or breast feeding * active gastrointestinal bleeding * residing in institutions (e.g. prison) * proctocolectomy
evaluation of depression symptoms and brain activity associated with response to treatment of depression

Conditions: Depression

Summary: this study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.

we are using depression symptom measurements and measurements of brain electrical activity (eeg) to determine what factors may influence whether a patient is likely to show a response to antidepressant medication, placebo, or only clinical visits (without the use of pills) during a treatment trial for depression.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of unipolar major depression exclusion criteria: * substance abuse * psychotic disorder * history of severe head trauma

Keywords: major depressive disorder mdd antidepressant
biomarkers of long covid (long covid_lcm)

Conditions: Long COVID

Summary: this observational prospective study is aimed to investigate noncoding rnas (ncrnas) such as micrornas (mirnas) and long noncoding rnas (lncrnas) as potential peripheral blood biomarkers of severity and poor prognosis in covid-19 patients. patients with intermittent or permanent symptoms after covid-19 at the moment of the recruitment were considered affected by long covid disease. in particular, the aim is to clarify if covid-19 biomarkers remain deregulated similarly in long covid patients. to this purpose, plasma and peripheral blood mononuclear cells (pbmcs) will be collected and patients will be compared to individuals who have never been affected by covid-19 or asymptomatic long covid patients.

the investigators will collect plasma and pbmcs from consenting subjects. the investigators will evaluate the expression of mirnas, lncrnas and cytokines in patients affected by long covid admitted to irccs policlinico san donato during the acute phase of covid-19. in particular, mirnas will be evaluated in plasma samples while lncrnas in pbmc samples to clarify their potential as biomarkers.

Eligibility criteria:
inclusion criteria: * previous covid-19 infection exclusion criteria: -
study of alloknesia in atopic dermatitis

Conditions: Atopic Dermatosis; Alloknesie

Summary: alloknesia is defined as pruritus (= itching) triggered by light mechanical stimuli, which are responsible for the perception of light touch under physiological conditions, but which are perceived as pruritic under pathological conditions. alloknesia occurs mainly in the context of chronic pruritus. consequently, patients suffering from chronic pruritus frequently perceive light touch sensations as pruritic, which can be particularly unpleasant and alter human interactions and quality of life on a daily basis. however, the epidemiology and burden of alloknesia have never been studied, whatever the cause of chronic pruritus. atopic dermatitis is one of the main diseases causing chronic itching, and patients frequently complain of alloknesia. in this study, we aim to investigate the frequency of alloknesia in patients with atopic dermatitis and to measure the consequences of alloknesia in these patients.


Eligibility criteria:
inclusion criteria: * age ≥18 years * no opposition from the patient * diagnosis of atopic dermatitis more than 6 months old exclusion criteria: * patients who are physically or mentally unable to complete the questionnaires. * patients on systemic treatment for 1 month or more * refusal to participate * patients under legal protection (guardianship, curatorship) * patients under court protection
metformin for the treatment of hidradenitis suppurativa (hs)

Conditions: Hidradenitis Suppurativa

Summary: a randomized controlled trial investigating the metformin is the treatment for hidradenitis suppurativa. metformin combined with doxycycline will be compared to the standard treatment of doxycycline monotherapy for hs severity and the effect on the pre-diabetic condition.


Eligibility criteria:
inclusion criteria: * age ≥18 years at baseline * a diagnosis of hs for at least 1 year prior to baseline * mild to moderately active disease defined by a hs physician global assessment (hs-pga) score of 2-3 and the refined hurley classification of mild to moderate at baseline * indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy. * able and willing to give written informed consent and to comply with the study requirements exclusion criteria: * pregnant and lactating women * concomitant diabetes mellitus * use of antibiotics within 14 days prior to baseline * use of immunosuppressing/modulating therapies within 28 days prior to baseline * a known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline
sharing histories: test of a teaching method for community health workers

Conditions: Infant Nutrition Disorders; Health Behavior

Summary: the purpose of this study is to determine the effectiveness of an innovative methodology for training community health workers that will improve their effectiveness in educating mothers to adopt best practice health behaviors in the home.

objective: training of community health workers (chw) is a growing priority to close the gap between health services and mothers/families in resource poor communities. to address research needs on how to improve effectiveness of chw training, the investigators tested an innovative chw teaching methodology called "sharing histories" hypothesizing that this would empower and enable chw to better teach mothers to improve health knowledge and behaviors that contribute to improved child growth. method: the study was a cluster-randomized controlled trial: 22 health facility jurisdictions were matched and randomly assigned as experimental or control. health personnel tutors and female chw were trained using either the "sharing histories" methodology (experimental) or a standard but still participatory teaching method (control). training content, materials, and other interventions were held constant between study groups. impact on maternal knowledge and practices, and child growth and morbidity were measured in representative household surveys at baseline, midterm, and final evaluation, with 600 mothers interviewed - 300 in each study group - at each point in time.

Eligibility criteria:
inclusion criteria: * adult interviewed must be mother or guardian of a child under two years of age. * child from birth (0.1 months-old) to under two years of age (23.9 months-old). exclusion criteria: * if a mother selected for interview had more than one child under age two years, only the younger child was considered for the interview and anthropometry measurements.

Keywords: sharing histories autobiographical memory health behavior narrative communication community health workers global health maternal and child health stunting